This study has determined in rats the ontogenetic schedule of the onset of pituitary prolactin (PRL) synthesis and release as well as of the establishment of the dopamine (DA) inhibitory control of PRL secretion. RIA recognized PRL traces in the pituitary at the 18th embryonic day (E18), although a clearly detectable amount of this hormone was first measured at E20, suggesting the onset of PRL synthesis. The PRL level in the pituitary increased significantly by E22, in females to a higher extent than in males. Decapitation of fetuses did not cause any change in the PRL plasma level in males showing no PRL release from the pituitary until term. Conversely, there was a slight but significant fall of plasma PRL in decapitated females, suggesting PRL release from the pituitary. An inhibition of DA receptors on lactotropes of fetuses resulted in an increased level of plasma PRL at E20, but not at E18, while the pituitary content of PRL remained unchanged. The same treatment at E22 caused a significant increase of the PRL concentration in plasma and a concomitant fall in the pituitary that could be prevented by preliminary encephalectomy. These data show that the tuberoinfundibular DA system begins to inhibit PRL release from lactotropes between E20 and E22, completely arresting PRL release from the pituitary in males but not in females.
Introduction
It is generally accepted that the tuberoinfundibular dopamine (DA) system in adult mammals ensures a neurohormonal inhibitory control of the pituitary prolactin (PRL) secretion. DA synthesized in the arcuate nucleus is delivered first via axons to the median eminence and then through the hypophysial portal circulation to the anterior lobe providing physiological action via D2 receptors on lactotropes (1) (2) (3) (4) . Although the development of the tuberoinfundibular DA system and differentiation of lactotropes have been repeatedly studied (5) (6) (7) (8) , there are only few and controversial data on the onset of PRL synthesis, release and regulation by tuberoinfundibular DA during ontogenesis (9) (10) (11) (12) (13) (14) . Thus, it is still uncertain whether the PRL secretion and its DA inhibitory control begin in rats before or after birth. Therefore, this study aimed to determine the exact period of the onset of PRL secretion and its DA inhibitory control in rats.
Materials and methods

Animals and experimental procedures
Wistar pregnant rats and fetuses at the 18th embryonic day (E18), E20 and E22 (the day of conception being E1) were used in this study. Fetuses were differentiated according to their sex at only one age, E22. In the first series of experiments, fetuses at E18 were either encephalectomized or decapitated in utero. This was followed by their removal at E22 under pentobarbital (50 mg/kg body weight) anesthesia and processing of fetal materials. Sham-operated animals served as controls. Encephalectomy and decapitation, described earlier (15, 16) , imitated switching off of the brain/hypothalamus or the brain/hypothalamus and pituitary respectively.
In the second series of experiments, pregnant females with intact and operated fetuses were intraperitoneally injected with haloperidol (0.75 mg/kg body weight; Gedeon Richter, Hungary), an inhibitor of DA receptors, on E18, E20 and E22. In the control group, pregnant females with intact or operated fetuses received saline instead of the drug. Ninety minutes following injections, fetuses were removed under pentobarbital anesthesia for subsequent processing of fetal materials.
In addition to surgically and pharmacologically treated animals, intact pregnant rats and fetuses were used in this study.
RIA
PRL was measured in the pituitaries and plasma at E18, E20 and E22 by standard RIA procedures using an NIDDK kit (NIDDK, Bethesda, MD, USA) provided by Dr A F Parlow. The minimal sensitivity was 0.5 ng/ml (for details see NIDDK rat PRL-RP-3 description). Fetal blood was collected from the heart with a heparinized Pasteur pipette, centrifuged at 600 g for 30 min at 4 ЊC, and plasma collected and frozen in liquid nitrogen and stored at ¹70 ЊC until assay. The plasma from six fetuses at E18, three fetuses at E20 and one fetus at E22 were pooled as single samples. Moreover, the pituitaries were rapidly removed from the skulls, weighed, frozen in liquid nitrogen and kept at ¹70 ЊC until RIA. Ten pituitaries at E18, six at E20 and three at E22 were pooled as individual samples. Before the RIA, the pituitaries and plasma were thawed, and PRL was extracted from the pituitaries according to the protocol of Shah & Hymer (17) . For this, pituitaries were homogenized in 0.05 mol/l Na 2 CO 3 buffer (pH 10), and 1 h later centrifuged at 1800 g for 30 min at 4 ЊC.
HPLC with electrochemical detection
HPLC with electrochemical detection was used to evaluate the concentration of DA in plasma of intact fetuses at E22. DA was extracted on acidic activated alumina and eluted in 0.6 M acetic acid. After centrifugation for 5 min at 1800 g, the supernatants were analyzed by means of reverse-phase liquid chromatography with electrochemical detection (Albedo 100, Europhor, Toulouse, France) at a potential of 700 mV. The chromatographic system consisted of a 20 ml sample loop leading to a 25 cm column (Kromasil, AIT, Paris, France) with a 4.6 mm internal diameter and 5 mm C-18 packing. The mobile phase consisted of an acetate buffer containing 134 mmol/l EDTA, 80 mmol/l octanesulfonic acid and 5% v/v methanol at pH 4.1.
Statistics
The results were statistically treated with a nonparametric Wilcoxon test.
Results
There were no differences in PRL concentrations in the pituitaries and plasma of saline-treated and sham-operated fetuses compared with intact fetuses, which made it possible to combine these data for the final analysis, and subsequently to refer to them as the controls.
Eighteenth fetal day
In control fetuses at E18, the PRL level in the pituitaries was below the resolution capacity of the applied technique ( Fig. 1) , although that in plasma was easily detectable (Fig. 2) . No change in the PRL concentration was detected in plasma of fetuses after their treatment with haloperidol ( Fig. 2) .
Twentieth fetal day
In control fetuses at E20, the PRL concentration in the pituitary had increased considerably, to the detectable level ( Fig. 1) , while that in plasma was the same as on E18 (Fig. 2) . Single injections of haloperidol to pregnant mothers resulted in a 2-fold increased concentration of PRL in fetal plasma (Fig. 2) . Conversely, no change was observed in the PRL pituitary level in the pharmacologically treated fetuses (Fig. 1) .
Twenty-second fetal day
PRL concentrations in the pituitary and in plasma of control fetuses at E22 significantly exceeded those in control fetuses at E20, being higher in females than in males (1.13 Ϯ 0.01 vs 0.9 Ϯ 0.01 ng/ml, P<0.05) (Figs 1 and 2 ). Single injections of haloperidol to pregnant rats resulted in significantly increased concentrations of PRL in plasma. The response to haloperidol in males exceeded by several fold that in females (Fig. 2) . In the same experiment, the pituitary concentration of PRL in males and females decreased approximately 2-fold compared with control fetuses (Fig. 1) .
Encephalectomy of male and female fetuses at E18 resulted in an increase of the PRL plasma level by E22 to the same level as in non-operated fetuses of the same age following their treatment with haloperidol (Fig. 2) . This was accompanied by a significant decrease of the pituitary PRL level (0.15 Ϯ 0.1 vs 1.6 Ϯ 0.1 ng/ml, P < 0.01) (Fig. 1) . The haloperidol treatment of encephalectomized male and female fetuses did not change PRL concentrations either in pituitaries or plasma compared with controls (Figs 1 and 2) .
Decapitation of male fetuses at E18 did not provoke any change in the PRL level in plasma at E22 while the same treatment of female fetuses resulted in a slight but significant decrease of the PRL concentration in plasma (1.13 Ϯ 0.01 vs 0.85 Ϯ 0.05 ng/ml, P < 0.05) (Fig. 2) . No change in the plasma PRL level was observed in decapitated males and females following their treatment with haloperidol (Fig. 2) .
The DA concentration in plasma of intact fetuses at E22 was 0.29 Ϯ 0.06 ng/ml in females and 0.31 Ϯ 0.02 ng/ml in males, showing no sex difference. 
Figure 2
The PRL plasma level in control and haloperidol-treated non-operated fetuses at E18, E20 and E22 (¹), haloperidol-treated and non-treated fetuses at E22 following encephalectomy at E18 (EN), and haloperidol-treated and non-treated fetuses at E22 following their decapitation at E18 (D). E, embryonic day; m, male; f, female. Values are means Ϯ S.E.M, (n) number of measurements, *P < 0.05, **P < 0.01 vs control by the non-parametric Wilcoxon test.
Discussion
PRL synthesis and release
Hitherto there were conflicting immunocytochemical and biochemical data about the onset of pituitary PRL synthesis and release in rats. According to some studies, PRL is synthesized and released in rat fetuses as early as several days before birth (9, 11, 14, 18, 19) , while others state that both processes begin mainly in the early postnatal period (10, 12, 13, (20) (21) (22) . This contradiction might be explained, at least in part, by technical reasons, e.g. by variations in the sensitivities of applied techniques and by the peculiarities of the different rat strains.
In this study, PRL traces were detected in the pituitaries of intact fetuses at E18, but this hormone became easily detectable only at E20, suggesting the onset of its synthesis. Although the PRL concentration in the pituitaries increased significantly during four subsequent fetal days, apparently there was practically no release of PRL into the general circulation of males and very low release in females at the end of the intrauterine development. Indeed, the plasma PRL level was not changed in decapitated males, i.e. in the absence of the brain/hypothalamus and pituitary, compared with that in non-operated fetuses. Still, in females decapitation resulted in a small but statistically significant fall of the PRL concentration. A low level of PRL delivery to the general circulation might be explained rather by the strong inhibitory control than by the immature mechanisms of PRL release. This hypothesis is indirectly supported by the in vitro observation of PRL release from lactotropes as early as at E19 (14) . A relatively high level of PRL in the general circulation of both intact and decapitated fetuses detected in this study apparently was maintained due to other potential sources of this hormone, e.g. placenta, uterus and the pituitary of the pregnant mother. Still, the permeability of the placental barrier for PRL in rats remains uncertain (23) (24) (25) .
DA control of PRL secretion
Some earlier studies have emphasized the retarded development of the tuberoinfundibular DA control of the pituitary PRL secretion compared with the neurohormonal regulation of secretion of other pituitary hormones, except thyroid-stimulating hormone (9, 26) . Indeed, in rats: (i) tyrosine hydroxylase-immunoreactive neurons of fetuses did not occupy the same region in the mediobasal hypothalamus as DA neurons in adults until the 3rd postnatal day (7); (ii) an inhibitor of DA receptors, pimozide, can provoke an increased concentration of PRL in the general circulation in postnatal rats not earlier than from the 4th day (9); and (iii) there was no inhibition of PRL secretion when co-incubating the pituitaries with hypothalamic extracts of fetuses and newborns (11) .
In this study, the DA control of the PRL secretion was evaluated in rat fetuses at E18, E20 and E22 after their treatment with haloperidol, an inhibitor of D2 receptors which are an attribute of lactotropes (27) . No changes in plasma and pituitary concentrations of PRL were observed at E18 after haloperidol treatment, showing no DA control of the PRL secretion. Haloperidol appeared to provoke PRL release from the pituitary first at E20, as shown by the increased concentration of PRL in plasma. However, there was no change in the pituitary PRL level, which might be explained by a low level of pituitary PRL, being at the limit of resolution of the applied RIA. Still, the hypothesis on the onset of the hypothalamic DA control of pituitary PRL release in rats at E20 is supported by the earlier observations, in rat fetuses of the same age, of: (i) catecholamine fluorescence in the mediobasal hypothalamus (8); (ii) expression of D2 receptors on lactotropes (28); (iii) lactotrope sensitivity to the DA agonist, apomorphine, in vitro (11); and (iv) a suppressive effect of the DA agonist, bromocriptine, on PRL discharge to the general circulation (29) . These data show the functional activity of the tuberoinfundibular DA system and the functional reactivity of the lactotropes in the rat as early as E20.
Haloperidol provoked the simultaneous increase of the PRL plasma level and the decrease of the PRL concentration in the pituitary at E22, definitely showing the onset of the hypothalamic control of PRL release. Surprisingly, this regulation is established when tyrosine hydroxylase immunoreactive neurons are detectable only in the ventrolateral mediobasal hypothalamus (7), i.e. in the position typical for peptidergic neurons co-expressing tyrosine hydroxylase but lacking aromatic L-amino acid decarboxylase. On the other hand, according to this and earlier studies (30) , there is a rather high level of DA in fetal plasma, being half that in the hypophysial portal circulation of adult rats (31) . In other words, it could not be excluded that besides the brain/hypothalamus there are other peripheral sources of DA production in the fetal organism contributing to the inhibitory control of the pituitary PRL secretion. However, this possibility can be ignored, since haloperidol failed to provoke PRL release in encephalectomized fetuses. Moreover, it should be emphasized that no change in the PRL plasma level was observed in decapitated fetuses after their treatment with haloperidol. All these data show that there are no other sources of PRL except the pituitary in the fetal organism under DA inhibitory control.
In spite of the permeability of the blood-brain barrier to haloperidol, one can exclude its influence on DA release from the mediobasal hypothalamus either due to a hypothetical autoregulation of DA neurons or via DA afferents on the neurons producing PRL releasing or inhibiting factors (vasoactive intestinal polypeptide, thyrotropin releasing-hormone, growth hormonereleasing hormone, DA, gamma-aminobutyric acid etc.). Indeed: (i) single systemic injection of haloperidol to adults did not change the rate of DA synthesis in the mediobasal hypothalamus at least for 12 h, showing no regulation of DA neurons of the arcuate nucleus via DA receptors (32); (ii) PRL response to haloperidol in adult rats was not modified after the preliminary surgical deafferentation of the mediobasal hypothalamus (33); (iii) thyrotropin releasing-hormone-producing neurons are not functionally active before birth (34) ; and (iv) there is practically no synaptic neurotransmission in the hypothalamus of fetal rats (35, 36) .
Thus, PRL synthesis begins in rats between E18 and E20, although there is no PRL release, at least in males, until term, apparently because of the strong DA inhibitory influence which is established between E20 and E22.
